Changes in symptoms and health-related quality of life in a nationally representative sample of adults in treatment for HIV

Lorenz, Karl A.; Cunningham, William E.; Spritzer, Karen L.; Hays, Ron D.
August 2006
Quality of Life Research;Aug2006, Vol. 15 Issue 6, p951
Academic Journal
journal article
Patient-centered measures of functioning and well-being are needed to monitor and improve health for HIV-infected persons. We estimated the associations between HRQOL and symptoms over time in HIV-infected persons, adjusting for demographic and clinical characteristics using a longitudinal study of a nationally representative cohort of 2267 patients in care for HIV infection surveyed in 1996 and again in 1998. We used two global measures of HRQOL (overall health and overall quality of life) scored to have a mean of 50 and standard deviation of 10 in the sample. The total number of symptoms decreased (-1.29, p<0.001 for the difference), and overall health (1.09, p<0.001 for the difference) and overall quality of life (1.31, p<0.001 for the difference) improved over the period. Controlling for baseline symptoms and HRQOL, each additional symptom at follow-up (B=-1.14, p<0.001) was associated with worsened overall health and worsened overall quality of life (B=-0.95, p<0.001). The association of two additional symptoms with lower global HRQOL was similar in magnitude to the effect of having significant depressive symptoms or the diagnosis of AIDS. In conclusion, among HIV-infected patients, symptoms are significantly related to HRQOL over time. The functioning and well-being of patients with HIV is inextricably linked to the symptoms they experience.


Related Articles

  • Outcomes of HIV Infection in Persons Who Resume Treatment after Interruptions.  // Annals of Internal Medicine;9/2/2008, Vol. 149 Issue 5, pI-30 

    The article presents a study to assess the risk for HIV-related infection and illness in persons receiving interrupted treatment who start continuous treatment. HIV-infected persons in 33 countires were assigned at random to receive continuous or interrupted treatment. The study found the blood...

  • POZitive living with HIV. Bomba, Ed // Philadelphia Gay News;11/15/2013, Vol. 37 Issue 46, p16 

    The article discusses ways on HIV-positive people can manage their health and life to ensure a good quality of life despite the illness. It explains the management that involves not just HIV medicine, but the possible, early onset of the diseases of aging and the medicines that go with them....

  • Heart of the matter.  // Echo Magazine;10/9/2003, Vol. 15 Issue 2, p54 

    Presents the results from physician and patient surveys released on September 16, 2003 in a supplement to the journal "JIAPAC," which revealed that HIV-positive patients receiving antiretroviral treatment are at increased risk for cardiovascular complications. Other risk factors associated with...

  • Prevalence and Correlates of Nonadherence to Antiretroviral Therapy in a Population of HIV Patients Using Medication Event Monitoring System®. Deschamps, Ann E.; De Graeve, Veerle; Van Wijngaerden, Eric; De Saar, Veerle; Vandamme, Anne-Mieke; Van Vaerenbergh, Kristien; Ceunen, Helga; Bobbaers, Herman; Peetermans, Willy E.; de Vleeschouwer, Peter J.; de Geest, Sabina // AIDS Patient Care & STDs;Nov2004, Vol. 18 Issue 11, p644 

    Nonadherence to antiretroviral therapy (ART) jeopardizes good clinical outcome in people living with HIV. In a single-center prospective study, prevalence and correlates of nonadherence were investigated in 43 patients on ART. Nonadherence was assessed using Medication Event Monitoring...

  • Eliminating Persistent HIV Infection: Getting to the End of the Rainbow. Margolis, David M.; Archin, Nancie M. // Journal of Infectious Diseases;6/15/2007, Vol. 195 Issue 12, p1734 

    This article comments on challenges that the medical fraternity faces to eradicate established HIV infection. The article makes specific reference to the study "Decay of the HIV Reservoir in Patients Receiving of Antiretroviral Therapy for Extended Periods: Implications for Eradication of...

  • Compromised Immunologic Recovery in Treatment-Experienced Patients with HIV Infection Receiving Both Tenofovir Disoproxil Fumarate and Didanosine in the TORO Studies. Negredo, Eugènia; Bonjoch, Anna; Paredes, Roger; Puig, Jordi; Clotet, Bonaventura // Clinical Infectious Diseases;9/15/2005, Vol. 41 Issue 6, p901 

    The effect of therapy with a combination of tenofovir and full-dose didanosine on increases in CD4+ cell count was examined in 2 large trials of treatment-experienced patients with human immunodeficiency virus (HIV) infection (the T- 20 versus Optimized Regimen Only [TORO] 1 and 2 clinical...

  • The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age. Vera, Jaime H.; Jackson, Akil; Dickinson, Laura; Else, Laura; Barber, Tristan; Mora-Peris, Borja; Back, David; Boffito, Marta; Winston, Alan // HIV Clinical Trials;02/01/2015, p39 

    Background: Antiretroviral safety and efficacy and may differ in older versus younger HIV-infected patients. The objective of this study was to assess the pharmacokinetic (PK) profile in older HIV-infected subjects (>60 years) switching combination antiretroviral therapy (cART) to a raltegravir...

  • Risk for Opportunistic Disease and Death after Reinitiating Continuous Antiretroviral Therapy in Patients with HIV Previously Receiving Episodic Therapy. El-Sadr, W. M.; Cohen, C. J.; Emery, S.; Lundgren, J. D.; Grund, B.; Neuhaus, J.; Phillips, A.; Neaton, J. D.; Babiker, A.; Darbyshire, J. // Annals of Internal Medicine;9/2/2008, Vol. 149 Issue 5, p289 

    Background: Episodic use of antiretroviral therapy guided by CD4+ cell counts is inferior to continuous antiretroviral therapy. Objective: To determine whether reinitiating continuous antiretroviral therapy in patients who received episodic treatment reduces excess risk for opportunistic disease...

  • Elvitegravir non-inferior to raltegravir in treatment-experienced patients.  // Infectious Disease News;Aug2011, Vol. 24 Issue 8, p12 

    The article focuses on a study which compared the effectiveness of once-daily elvitegravir and twice-daily raltegravir in treating HIV-1 infected patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics